- Secondary prevention of coronary heart disease and peripheral artery disease combining antiaggregation and anticoagulation therapy. Expert consensus statement of the Czech Society of Cardiology, the Czech Society of Internal Medicine and the Czech Society of Angiology to the outcomes of COMPASS trial2019 | Third Faculty of Medicine, Faculty of Medicine in Pilsen, First Faculty of Medicine
- Secondary prevention of coronary heart disease and peripheral artery disease combining antiaggregation and anticoagulation therapy. Expert consensus statement of the Czech Society of Cardiology, the Czech Society of Internal Medicine and the Czech Society of Angiology to the outcomes of COMPASS trial2019 | Third Faculty of Medicine, Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial2019 | Third Faculty of Medicine
- Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events A Secondary Analysis of the COMPASS Trial2022 | Central Library of Charles University
- Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial2022 | Third Faculty of Medicine
- Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease Insights From the COMPASS Trial2020 | Third Faculty of Medicine
- Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial2017 | Third Faculty of Medicine
- Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial2021 | Publication without faculty affiliation
- Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial2020 | Third Faculty of Medicine
- Total Events and Net Clinical Benefit of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial2023 | Third Faculty of Medicine
- Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial2022 | Third Faculty of Medicine
- Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study2019 | Third Faculty of Medicine
- Is it time to replace acetylsalicylic acid monotherapy in secondary prevention with a more effective treatment?2022 | Third Faculty of Medicine
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial2018 | Third Faculty of Medicine
- Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis2019 | Third Faculty of Medicine
- Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)2020 | Third Faculty of Medicine